Sanguine Resources

News | Events | Case Studies | Spotlight

Monitoring Systemic Lupus Erythematosus Longitudinally

Systemic lupus erythematosus (SLE), also known as lupus, is a chronic autoimmune disease caused by random or inherited mutations in various genes of the immune system. It affects the skin, joints, kidneys, brain, and almost every other organ. People suffering from SLE experience inflammation in the connective tissues that provide strength and flexibility to structures throughout the body.

Recovered Coronavirus Patient Donates Blood To Help Vaccine, Treatment Research

WBZ | CBS Boston – Lara Woolfson’s COVID-19 story and her participation with Sanguine for her in-home blood sample collection. Transcript: Headline News: Live from the Channel 4 Studios in Boston, this is WBZ news at 5:30. Liam Martin: Well for a photographer from Boston who has already recovered from the coronavirus is hoping that her fight with it will help others recover as well.

PODCAST: The Bio Report: Bringing the Trial to the Patient

One of the challenges to securing the participation of patients in clinical trials can be simple geography. Sanguine Biosciences is seeking to tear down that barrier to participation by using mobile technology to bring clinical trials to patients. The company recently partnered with Vir Biotechnology to complete a COVID-19 clinical study aimed at better understanding the biology of the disease by sending healthcare personnel to collect blood samples from patients at their homes.

COVID-19: Navigating the Pandemic: COVID-19’s potential impact on the global pharmaceutical market?

  COVID-19 has spread to more than 60 countries, causing tens of thousands of illnesses and thousands of deaths. Pharma companies, biotechs, governments, academic institutions, nonprofits and others are all racing to develop a treatment, a cure and a vaccine. In this Sanguine Speaker Series (3) virtual fireside chat, we will discuss: Response efforts to the current COVID-19 pandemic How does the race for the cure affect the hundreds of other drugs in development COVID-19’s potential impact on the global pharmaceutical market?

PFE-001: A Novel Non-Covalent Modulator of Hemoglobin Improves Anemia and Reduces Sickling in a Mouse Model of Sickle Cell Disease

Speaker: Kelly M. Knee, PhD, Senior Principal Scientist, Rare Disease Researcher Unit, Pfizer Sickle cell disease is a severe genetic disorder caused by a single point mutation on the β-chain of adult hemoglobin (Hb A), β6 Glu→Val (Hb S). Numerous small molecules which covalently bind to Hb S have been evaluated clinically, however, the molecules that have demonstrated clinical efficacy all carry a reactive aldehyde group.

COVID-19: Navigating the Pandemic: – How with COVID-19 effect research studies and clinical trials?

COVID-19 has spread to more than 60 countries, causing tens of thousands of illnesses and thousands of deaths. Pharma companies, biotechs, governments, academic institutions, nonprofits and others are all racing to develop a treatment, a cure and a vaccine. Moderator: Craig Lipset Independent Advisor, Former Head of Clinical Innovation, Pfizer Panelists: Brian Neman CEO and Co-Founder, Sanguine Lisa Tindell Vice President, Clinical Research Operations at Minneapolis Heart Institute Foundation Sal Salamone Editor in Chief, RTInsights.com

Biospecimen Donation: Personal Journey of a Family and Genetic Diagnostic Lab Advancing Biomedical Research

Author Sarah Gray shares her story of how she anonymously donated her infant son’s post-mortem tissue for biomedical research to some of the most prestigious scientific facilities in the country. Years later, after tracking down each donation, Sarah met with the research scientists that received the donations to learn how they are being studied in cutting-edge research for medical discoveries.

Implementing AI: The Effects of AI in Drug Development

Join our distinguished Novartis speaker, Shruthi Bharadwaj, PhD as she speaks about her experience in AI including: With the costs to commercialize a new drug is dramatically increasing to over $2 billion, AI brings the opportunity to assist pharma companies to bring new drugs and therapies to the market faster. 

Same Day Collection and Delivery Key Facts

Certain disease studies exploring sensitive biomarkers or molecules with a short half-life require blood analysis soon after collection to prevent important blood components from breaking down, which may have a negative effect on study results. Numerous factors such as diet, medications, supplements, and patient hydration can affect blood test results.

San Francisco Chronicle

Antibodies in recovered victums’ blood may hold key to COVID-19 cure In the race to develop treatments for the coronavirus, two California biotech companies are teaming up to collect blood samples from people who have recovered from COVID-19 — with the hope that antibodies produced by their immune system after being infected can provide the key to developing a drug or vaccine.